Skip to main content
SpringerLink
Log in
Book cover

The Inflammasomes pp 209–220Cite as

Treatment of Inflammasome-Related Disorders

  • Chapter
  • First Online:

  • 1194 Accesses

Part of the book series: Progress in Inflammation Research ((PIR))

Abstract

IL-1β appears to play a key role in a wide variety of inflammatory diseases. Conditions range from the very rare such as the inherited autoinflammatory disorders particularly cryopyrin-associated periodic syndrome (CAPS) to much common acquired disorders such as gout [1], silica-mediated pulmonary fibrosis [2], as well as perhaps myeloma [3], atherosclerosis [4], and type II diabetes mellitus [5].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF (2007) Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 66(12):1683–1684

    Article  PubMed  CAS  Google Scholar 

  2. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J (2008) Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320(5876):674–677

    Article  PubMed  CAS  Google Scholar 

  3. Lust JA, Lacy MQ, Zeldenrust SR et al (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 84(2):114–122

    Article  PubMed  CAS  Google Scholar 

  4. Duewell P, Kono H, Rayner KJ et al (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464(7293):1357–1361

    Article  PubMed  CAS  Google Scholar 

  5. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32(9):1663–1668

    Article  PubMed  CAS  Google Scholar 

  6. Wannamaker W, Davies R, Namchuk M et al (2007) (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoy l)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther 321(2):509–516

    Article  PubMed  CAS  Google Scholar 

  7. Linton SD (2005) Caspase inhibitors: a pharmaceutical industry perspective. Curr Top Med Chem 5(16):1697–1717

    Article  PubMed  CAS  Google Scholar 

  8. Hawkins PN, Lachmann HJ, McDermott MF (2003) Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 348(25):2583–2584

    Article  PubMed  Google Scholar 

  9. Goldbach-Mansky R, Dailey NJ, Canna SW et al (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355(6):581–592

    Article  PubMed  CAS  Google Scholar 

  10. Neven B, Marvillet I, Terrada C et al (2010) Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 62(1):258–267

    Article  PubMed  CAS  Google Scholar 

  11. Hoffman HM, Throne ML, Amar NJ et al (2008) Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58:2443–2452

    Article  PubMed  CAS  Google Scholar 

  12. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al (2009) Use of canakinumab in cryopyrin-associated periodic syndrome. N Engl J Med 360(23):2416–2425

    Article  PubMed  CAS  Google Scholar 

  13. Kuemmerle-Deschner JB, Lachmann HJ, Hachulla E et al (2009) Efficacy and safety of canakinumab (Ilaris) in a large cohort of patients across different severity phenotypes of cryopyrin associated periodic syndrome (CAPS). ACR, abstract 1235

    Google Scholar 

  14. Glaser RL, Goldbach-Mansky R (2008) The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies. Curr Allergy Asthma Rep 8(4):288–298

    Article  PubMed  CAS  Google Scholar 

  15. Chae JJ, Wood G, Masters SL et al (2006) The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 103(26):9982–9987

    Article  PubMed  CAS  Google Scholar 

  16. Calligaris L, Marchetti F, Tommasini A, Ventura A (2008) The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 167(6):695–696

    Article  PubMed  Google Scholar 

  17. Moser C, Pohl G, Haslinger I et al (2009) Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant 24:676–678

    Article  PubMed  CAS  Google Scholar 

  18. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P (2009) Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 161(5):1199–1201

    Article  PubMed  CAS  Google Scholar 

  19. Simon A, Bodar EJ, van der Hilst JC et al (2004) Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 117(3):208–210

    Article  PubMed  CAS  Google Scholar 

  20. Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A (2005) Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 63:260–264

    PubMed  CAS  Google Scholar 

  21. Gattorno M, Pelagatti MA, Meini A et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58(5):1516–1520

    Article  PubMed  CAS  Google Scholar 

  22. van der Hilst JC, Bodar EJ, Barron KS et al (2008) Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 87(6):301–310

    Article  Google Scholar 

  23. Aksentijevich I, Masters SL, Ferguson PJ et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360(23):2426–2437

    Article  PubMed  CAS  Google Scholar 

  24. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201(9):1479–1486

    Article  PubMed  CAS  Google Scholar 

  25. Verbsky JW, White AJ (2004) Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31(10):2071–2075

    PubMed  Google Scholar 

  26. Kalliolias GD, Liossis SN (2008) The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 17(3):349–359

    Article  PubMed  CAS  Google Scholar 

  27. Lequerre T, Quartier P, Rosellini D et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67(3):302–308

    Article  PubMed  CAS  Google Scholar 

  28. Gattorno M, Piccini A, Lasiglie D et al (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58(5):1505–1515

    Article  PubMed  CAS  Google Scholar 

  29. Zeft A, Hollister R, LaFleur B et al (2009) Anakinra for systemic juvenile arthritis: the rocky mountain experience. J Clin Rheumatol 15(4):161–164

    Article  PubMed  Google Scholar 

  30. Lovell DJ, Giannini EH, Kimura Y et al (2007) Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis. ACR, abstract 1282

    Google Scholar 

  31. Lovell DJ, Giannini EH, Kimura Y et al (2009) Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. ACR, abstract 2053

    Google Scholar 

  32. Ruperto N, Quartier P, Wulffraat N et al (2009) ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody has a beneficial effect in children with systemic juvenile idiopathic arthritis. ACR, abstract 2109

    Google Scholar 

  33. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237–241

    Article  PubMed  CAS  Google Scholar 

  34. So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2):R28

    Article  PubMed  Google Scholar 

  35. So A, De Meulemeester D, Shamim T et al (2009) Canakinumab (ACZ885) vs. triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients refractory to or contraindicated to NSAIDs and/or colchicine. ACR, abstract LB4

    Google Scholar 

  36. Terkeltaub R, Sundy JS, Schumacher HR et al (2009) The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study. Ann Rheum Dis 68:1613–1617

    Article  PubMed  CAS  Google Scholar 

  37. Schumacher RH, Sundy JS, Terkeltaub R et al (2009) Placebo-controlled study of rilonacept for prevention of gout flares during initiation of urate-lowering therapy. EULAR, abstract 426

    Google Scholar 

  38. McGonagle D, Tan AL, Madden J, Emery P, McDermott MF (2008) Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 58(2):631–633

    Article  PubMed  Google Scholar 

  39. Announ N, Palmer G, Guerne PA, Gabay C (2009) Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 76(4):424–426

    Article  PubMed  Google Scholar 

  40. de Koning HD, Bodar EJ, van der Meer JW, Simon A (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 37(3):137–148

    Article  PubMed  Google Scholar 

  41. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA (2008) Resistant Behcet disease responsive to anakinra. Ann Intern Med 149(4):284–286

    PubMed  Google Scholar 

  42. Wendling D, Govindaraju S, Prati C, Toussirot E, Bertolini E (2008) Efficacy of anakinra in a patient with refractory relapsing polychondritis. Joint Bone Spine 75(5):622–624

    Article  PubMed  Google Scholar 

  43. Delluc A, Limal N, Puechal X, Frances C, Piette JC, Cacoub P (2008) Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann Rheum Dis 67(2):278–279

    Article  PubMed  CAS  Google Scholar 

  44. Cassel SL, Eisenbarth SC, Iyer SS et al (2008) The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 105(26):9035–9040

    Article  PubMed  CAS  Google Scholar 

  45. Dostert C, Guarda G, Romero JF et al (2009) Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One 4(8):e6510

    Article  PubMed  Google Scholar 

  46. Watanabe H, Gaide O, Petrilli V et al (2007) Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 127(8):1956–1963

    Article  PubMed  CAS  Google Scholar 

  47. Omi T, Kumada M, Kamesaki T et al (2006) An intronic variable number of tandem repeat polymorphisms of the cold-induced autoinflammatory syndrome 1 (CIAS1) gene modifies gene expression and is associated with essential hypertension. Eur J Hum Genet 14(12):1295–1305

    Article  PubMed  CAS  Google Scholar 

  48. Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356(15):1517–1526

    Article  PubMed  CAS  Google Scholar 

  49. Donath MY, Weder C, Brunner A et al (2009) XOMA 052, a potential disease modifying anti-IL-1beta antibody, shows sustained HbA1c reductions 3 months after a single injection with no increases in safety parameters in subjects with type 2 diabetes. ADA, abstract 113-OR

    Google Scholar 

  50. Abbate A, Kontos MC, Grizzard JD et al (2010) Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 105(10):1371–1377.e1

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCL Medical School, National Amyloidosis Centre, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK

    Helen J. Lachmann

Authors
  1. Helen J. Lachmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helen J. Lachmann .

Editor information

Editors and Affiliations

  1. Institut de Transgénose, Labo. d'Immunologie et, CNRS, rue de la Férollerie 3B, Orléans CX 2, 45071, France

    Isabelle Couillin

  2. CNRS UMR 5201, Labo. Génétique et Cancer, Université de Lyon I, rue Laënnec 28, Lyon, 69008, France

    Virginie Pétrilli

  3. Dept. Immunology & Infectious, Diseases, Harvard School of Public Health, Huntington Ave. 651, Boston, 02115-6017, Massachusetts, USA

    Fabio Martinon

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Basel

About this chapter

Cite this chapter

Lachmann, H.J. (2011). Treatment of Inflammasome-Related Disorders. In: Couillin, I., Pétrilli, V., Martinon, F. (eds) The Inflammasomes. Progress in Inflammation Research. Springer, Basel. https://doi.org/10.1007/978-3-0348-0148-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-0148-5_14

  • Published:

  • Publisher Name: Springer, Basel

  • Print ISBN: 978-3-0348-0147-8

  • Online ISBN: 978-3-0348-0148-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation